View Item 

Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: a survey of GPs’ awareness and knowledge

Access Status
Fulltext not available
Authors
Munro, A.
Codde, J.
Semmens, James
Leung, Y.
Spilsbury, Katrina
Williams, Vincent
Steel, N.
Cohen, P.
Pavicic, H.
Westoby, V.
O'Leary, Peter
Date
2015
Type
Journal Article

Metadata
Show full item record
Citation
Munro, A. and Codde, J. and Semmens, J. and Leung, Y. and Spilsbury, K. and Williams, V. and Steel, N. et al. 2015. Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: a survey of GPs’ awareness and knowledge. Australian Family Physician. 44 (1-2): pp. 64-68.
Source Title
Australian Family Physician
Additional URLs
ISSN
School
Centre for Population Health Research
URI
Collection
Abstract

Background - Patients have an increased risk of persistent/recurrent cervical disease if they received treatment for a high-grade squamous intraepithelial lesion (HSIL). Consequently, understanding whether co-testing (human papillomavirus [HPV] DNA testing and cervical cytology) is fully utilised by general practitioners (GPs) is paramount. Methods - After consultation with key stakeholders, an anonymous, self-completion questionnaire was developed and disseminated to GPs who had provided cervical cytology. Results - Responses were received from 745 GPs (30.9% response rate). A significant number (34.3%) of GPs were unaware of the use of co-testing (HPV DNA testing and cervical cytology) for the management of patients after HSIL treatment. Additionally, the majority of GPs reported they did not ‘always’ receive a clear follow-up plan for patients after treatment of an HSIL. Discussion - GPs require further support and education to ensure successful adoption of co-testing (HPV DNA testing and cervical cytology), specifically, for patients treated for an HSIL.